NEW YORK — French diagnostics firm Novacyt reported on Friday a massive increase in revenues for the full-year 2020 amid high demand for its SARS-CoV-2 testing products and the recent acquisition of a PCR instrument manufacturing partner.
For the 12-month period ended Dec. 31, 2020 Novacyt generated revenues of €311.6 million ($378.5 million) compared with €13.1 million the year before.